Scientific Frontline: "At a Glance" Summary
- Main Discovery: Neoadjuvant treatment with the immunotherapy drug pembrolizumab significantly shrinks or eliminates tumors in patients with desmoplastic melanoma, a rare and aggressive form of skin cancer.
- Methodology: In the SWOG S1512 clinical trial (Cohort A), researchers administered three infusions of pembrolizumab over a nine-week period to 28 patients with surgically resectable desmoplastic melanoma prior to their scheduled surgery.
- Key Data: Pathologic analysis revealed that 71% of patients had no detectable live tumor cells at the time of surgery, and at the three-year follow-up, 95% of patients survived with a 74% disease-free recurrence rate.
- Significance: This therapeutic approach can spare patients from extensive, potentially disfiguring surgeries and postoperative radiation, drastically improving quality of life without compromising survival outcomes.
- Future Application: The findings support a paradigm shift toward using PD-1 blockade immunotherapy as the standard neoadjuvant care for resectable desmoplastic melanoma, replacing immediate invasive excision.
- Branch of Science: Oncology, Immunology, and Dermatology.
- Additional Detail: Desmoplastic melanoma, typically resistant to chemotherapy and radiation, was found to be highly responsive to PD-1 blockade due to its high mutational burden caused by UV damage.




.jpg)

.jpg)


